Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab and mDCF in Resectable Esophago-Gastric Adenocarcinoma
NCT03288350Phase 2Unknown
- Sponsor
- McGill University Health Centre
- Start
- Feb 2018
- Primary completion
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of avelumab in gastric adenocarcinoma, esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma, sponsored by McGill University Health Centre. Status: unknown.
02
Drugs
avelumab
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03288350.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03288350.